A Phase III Equivalence Trial of Azithromycin versus Benzathine Penicillin for Treatment of Early Syphilis | Zendy

Edward W. Hook | Zendy; Frieda Behets | Zendy; Kathleen Van Damme | Zendy; Noro Lantoniaina Rosa Ravelomanana | Zendy; Peter A. Leone | Zendy; Arlene C. Seña | Zendy; David H. Martin | Zendy; Carol Langley | Zendy; Linda M. McNeil | Zendy; Mark Wolff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Phase III Equivalence Trial of Azithromycin versus Benzathine Penicillin for Treatment of Early Syphilis

Author(s) -

Edward W. Hook,

Frieda Behets,

Kathleen Van Damme,

Noro Lantoniaina Rosa Ravelomanana,

Peter A. Leone,

Arlene C. Seña,

David H. Martin,

Carol Langley,

Linda M. McNeil,

Mark Wolff

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/652239

Subject(s) - azithromycin , medicine , syphilis , penicillin , adverse effect , randomized controlled trial , antibiotics , immunology , human immunodeficiency virus (hiv) , microbiology and biotechnology , biology

Syphilis remains an important source of morbidity worldwide. Long-acting penicillin is the only therapy currently recommended for syphilis in much of the world. Because of hesitation to use penicillin for fear of anaphylaxis, there is a need for an effective, well-tolerated alternative to penicillin for syphilis therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research